The pharmacokinetics of dibekacin, a new aminoglycoside antibiotic, was studied in volunteers given the same dose (100 mg) intramuscularly on two separate occasions and intravenously at two different rates of infusion. The kinetic parameters (t1/2, 2.24 h, and Vd, 0.136 liter/kg, as the overall mean) observed after intramuscular administration appear to be compatible with those of other aminoglycosides and fairly reproducible within the same individuals. Dibekacin was rapidly absorbed (tmax, 0.84 h), yielding a peak level of 10.4 ,tg/ml after the 100-mg intramuscular dose. After the 30-or 60-min infusion, the concentrations of dibekacin in serum fell bi-exponentially, giving an elimination half-life (t,/2p) of 2.50 to 2.88 h. The highest serum levels after the 30-and 60-min infusions were 15.2 ± 0.9 and 12.1 ± 1.8 ,ug/ml, respectively. Serum levels at 6 h after completion of infusions were 1.9 ± 0.3 and 1.7 ± 0.4 ,ug/ml, respectively. Dibekacin (3',4'-dideoxykanamycin B), a synthetic derivative of kanamycin B, has significantly greater activity than its parent compound against Escherichia coli and Pseudomonas aeruginosa (20). Thus, the minimum inhibitory concentrations (MICs) of dibekacin range from 1.56 to 3.12 and 3.12 to 6.25 ,ug/ml for strains of E. coli and P. aeruginosa, respectively, for which the MICs of kanamycin exceed 50 ,ug/ml (20) .
The pharmacokinetics of dibekacin, a new aminoglycoside antibiotic, was studied in volunteers given the same dose (100 mg) intramuscularly on two separate occasions and intravenously at two different rates of infusion. The kinetic parameters (t1/2, 2.24 h, and Vd, 0.136 liter/kg, as the overall mean) observed after intramuscular administration appear to be compatible with those of other aminoglycosides and fairly reproducible within the same individuals. Dibekacin was rapidly absorbed (tmax, 0.84 h), yielding a peak level of 10.4 ,tg/ml after the 100-mg intramuscular dose. After the 30-or 60-min infusion, the concentrations of dibekacin in serum fell bi-exponentially, giving an elimination half-life (t,/2p) of 2.50 to 2.88 h. The highest serum levels after the 30-and 60-min infusions were 15 .2 ± 0.9 and 12.1 ± 1.8 ,ug/ml, respectively. Serum levels at 6 h after completion of infusions were 1.9 ± 0.3 and 1.7 ± 0.4 ,ug/ml, respectively. Dibekacin (3',4'-dideoxykanamycin B), a synthetic derivative of kanamycin B, has significantly greater activity than its parent compound against Escherichia coli and Pseudomonas aeruginosa (20) . Thus, the minimum inhibitory concentrations (MICs) of dibekacin range from 1.56 to 3.12 and 3.12 to 6.25 ,ug/ml for strains of E. coli and P. aeruginosa, respectively, for which the MICs of kanamycin exceed 50 ,ug/ml (20) .
Since dibekacin has some promise for treating infections with gram-negative bacilli and since a knowledge of its pharmacokinetic properties is needed to develop both effective and safe dosage schedules, we have undertaken an investigation of these characteristics. This study was undertaken specifically to (i) elucidate the distribution and elimination kinetics of dibekacin in humans after a single intravenous or intramuscular administration and (ii) develop dosage schedules and methods of administration compatible with observed pharmacokinetic parameters.
MATERIALS AND METHODS Human volunteers. Five adult male volunteers with no known allergies to antibiotics or other drugs participated in this study after informed written consent had been obtained. None had taken any drug during the month before the investigational period. Their ages ranged from 23 to 54 years (mean ± standard deviationeSD], 36.8 ± 14.1 years), and their body weights ranged from 45 to 62 kg (56.4 ± 6.1 kg). Results of prestudy physical examination and pre-and postdrug laboratory findings were normal. Because of concerns with the nephrotoxicity of aminoglycosides, it is noteworthy that their serum creatinine values ranged from 1.05 to 1.30 mg/100 ml (1.18 ± 0.08 mg/100 ml) during the study period.
Dosage. Dibekacin sulfate (lot RDK-K-14; Meiji Seika Research Laboratories, Tokyo, Japan) was used throughout this study. It was dissolved in 0.9% saline at the concentration of 50 mg/ml for intramuscular administration. For intravenous use, the 100-mg dose was dissolved in 200 ml of 0.9% saline.
Experimental design. Each of the five volunteers received a 100-mg dose (mean ± SD, 1.79 ± 0.22 mg/ kg) intramuscularly and intravenously on two separate occasions. One intravenous dose was infused over a 30-min period (3.59 ± 0.44 mg/kg per h), and the second was infused over 60 min (1.79 ± 0.22 mg/kg per h). Treatments were randomized and delivered in a crossover fashion, with monthly intervals separating the respective doses. Subjects were fasted overnight before each study; food was also withheld for 2 h after dosage. An automatic infusion pump (type AIP-2H, no. 2487; Atom Apparatus Co., Tokyo, Japan) was used for intravenous infusion.
Blood specimens (5 ml each) were drawvn from an arm vein at 0.25, 0.5, 1, 2, 3, 4, and 6 h after intramuscular administration and at 0 (immediately after intravenous infusion ceased), 0.25, 0.5, 1, 1.5, 2, 4, and 6 h after intravenous infusion. Samples were always withdrawn from the arm contralateral to that used for infusion.
Microbiological assay. Assays were performed on each study day as serum was collected. The concentrations of dibekacin in serum were determined by an agar (streptomycin assay agar; BBL Microbiology Systems, Cockeysville, Md.) diffusion test (cup plate method), using Bacillus subtilis ATCC 6633 as the VOL. 18, 1980 test organism. Reference standards were diluted (8, 4, 2, 1, and 0.5 ,ug of dibekacin per ml concentrations) in pooled human serum. Each agar plate contained a homologous standard comprising three points and three test assays, with 1:3, 1:6, and 1:12 dilutions for each assay. After incubation at 37°C for 16 to 18 h, the zones of inhibition were measured, and the antibiotic concentrations were determined by graphical comparison of the mean zone of inhibition of each sample with the mean zones of inhibition of standard dilutions. With this method, concentrations of 0.2 ug of dibekacin per ml or greater in serum could be determined.
Calculation of pharmacokinetic constants. Unweighted serum concentration data (Ct) after single intramuscular doses of dibekacin were fitted to a onecompartment open model by using the following equation (25):
Three constants can be determined in this equation: Ka, the apparent first-order absorption rate constant (hour-'); Ke,. the apparent first-order elimination rate constant (hour-'); Vd, the apparent volume of distribution (liter). The value of Vd was calculated by assuming complete absorption (F = 1.0). The other factors in the equation are serum drug concentration in micrograms per milliliter (C), dose in milligrams (D), and time (t) in hours. The predicted time of the peak serum level after intramuscular administration of dibekacin (tm.,) was calculated by using the following equation (7):
Ka -Kel Kel The postinfusion Ct data of dibekacin were fitted to the following biexponential equation (6): Ct= R-e`' + Se-t (3) in which R, S, a (hour-'), and ,B (hour -1) denote the hybrid constant and t denotes the postinfusion time.
The apparent volume of distribution (Vd,) was directly calculated by the method of Wagner (23) . The distribution rate constants k12 and k21 (hour-'), k13 (hour-'), 
RESULTS
The average concentrations of dibekacin in serum after intramuscular administration of 100 mg were indistinguishable in the two trials (Fig.  1) . The observed maximum concentrations (Cmax) ranged from 8.8 to 11.7 (10.1 ± 1.0) yg/ml and from 8.5 to 12.9 (10.7 ± 1.5) tig/ml in trials 1 and 2, respectively. The peak time (tmax) was observed at 0.5 h (three times) or at 1 h (seven times) after intramuscular administration of dibekacin in all subjects. The mean predicted tmax calculated by using equation 2 was 0.81 and 0.85 h in trials 1 and 2 respectively ( Table 1) .
The mean data on kinetic disposition of dibekacin after the intramuscular administration, analyzed by using equation 1, have been summarized in Table 1 are shown in Fig. 2 . Pharmacokinetic parameters calculated from application of the two-compartment open-model methodology (6) are given in Table 2 . The postinfusion Cmax (15.2 ± 0.9 ,ug/ ml) after the 30-min infusion was significantly higher (P < 0.02) than that after the 60-min infusion (12.1 ± 1.8 ,ig/ml). This trend continued for 1 h after the end of infusion (Fig. 2 ), but had disappeared by 6 h, when mean Ct values approximated 2 ,ug/ml. The Vd, for dibekacin administered intravenously ranged from 14 to 16% of body weight (Table 2 ). Other pharmacokinetic parameters were not affected by the rate of infusion ( Table 2 ). The mean values for t,12B, [AUCI& and C4ot obtained with intravenous infusion were not different from the values obtained after intramuscular administrations. DISCUSSION The above observations suggest that the pharmacokinetic properties of dibekacin are similar to those of other aminoglycoside antibiotics (1, 9, 14) . Thus, the t1/2 of dibekacin when administered intramuscularly is close to the values reported for gentamicin (13, 16) , tobramycin (13, 16) , amikacin (3, 4) , kanamycin (3, 4) , and sisomicin (17) delivered by the same route.
The mean values of Vd and Vd. for dibekacin (Tables 1 and 2 h-1 after the 60-min infusion, was close to the constants of gentamicin, tobramycin, and sisomicin after such an infusion (11) .
The mean Cm levels of dibekacin in serum after the 30-and 60-min infusions of a 100-mg dose were 15.2 and 12.1 ,ug, respectively (Table   2) , but levels at 6 h approximated 2 ,tg/ml, irrespective of infusion rate. These observations, which suggest that the MICs of 1.56 to 3.12 and 3.12 to 6.25 ,ug/ml required for E. coli and P. aeruginosa (20) , respectively, would be exceeded for the same time when 100 mg of dibekacin is infused with either schedule, might favor the use of the 60-min schedule with its lower peak serum levels and possibly lower toxicity.
Aminoglycosides are usually administered at 6-to 8-h intervals, a procedure which yields high peak serum concentrations (18, 26) and troughs below the MICs of such derivatives as gentamicin sulfate, sisomicin, and tobramycin for many gram-negative bacilli (8, 16, 17, 18, 26) . These dips to subinhibitory concentrations may be a liability for the neutropenic patient with inadequate host defense mechanisms (2) . Recent studies have indicated that aminoglycosides may be more effective when administered by continuous infusions than by intermittent injections (2, 5, 21) . Their efficacy might be further improved by using a schedule which would maintain at all times the serum concentration above the MIC of the antibiotic against infecting organisms (2). To sustain a serum level of 7 ug/ml, which is greater than the MIC of dibekacin (20) for P. aeruginosa, in a 70-kg patient with nornal renal function would require an infusion of 0.374 mg/ min. To obtain a concentration of 7 jig of dibekacin per ml of serum rapidly would require a loading dose of 66 mg to be administered intramuscularly.
